Abstract
Background: Anti-PD-1/L1 antibodies could be an optional therapy for EGFR-TKI-resistant non-small cell lung cancer (NSCLC) patients with EGFR mutation. However, little is known about PD-L1 expression in advanced NSCLC patients with the T790M-positive EGFR mutation, as well as the changes induced by osimertinib treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
